<DOC>
	<DOCNO>NCT02740387</DOCNO>
	<brief_summary>This 1-year , multicenter , Phase 2 , open-label safety study subject unilateral Meniere 's disease . Subjects receive 1 intratympanic ( IT ) injection 12 mg OTO-104 3-month interval total 4 injection total .</brief_summary>
	<brief_title>Open Label Study OTO-104 Subjects With Meniere 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Meniere Disease</mesh_term>
	<criteria>Inclusion Criteria include , limited : Subject diagnosis definite unilateral Meniere 's disease . Subject agree maintain current standard care treatment Meniere 's disease onstudy . Exclusion Criteria include , limited : Subject infection ear , sinus , upper respiratory system . Subject pregnant lactating . Subject history immunodeficiency disease . Subject active recent ( &lt; 1 month prior screen ) middle ear disease , include limited : chronic otitis medium , acute otitis medium , middle ear effusion , middle ear atelectasis , cholesteatoma . Subject experience adverse reaction intratympanic injection steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>